KRTX — Karuna Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $12.58bn
- $11.32bn
- $0.65m
Annual income statement for Karuna Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 37 | 10.6 | 0.654 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 45.4 | 71.8 | 182 | 300 | 495 |
| Operating Profit | -45.4 | -71.8 | -145 | -290 | -495 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -44 | -68.5 | -144 | -275 | -433 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -44 | -68.6 | -144 | -276 | -434 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -44 | -68.6 | -144 | -276 | -434 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -44 | -68.6 | -144 | -276 | -434 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.69 | -2.59 | -4.92 | -8.74 | -11.7 |